- |||||||||| Latuda (lurasidone oral) / Sumitomo Dainippon
Journal: Ratings surveillance and reliability in a study of major depressive disorder with subthreshold hypomania (mixed features). (Pubmed Central) - Apr 26, 2019 P3 In this network meta-analysis, lurasidone was found to be more efficacious than aripiprazole and ziprasidone, and was associated with less weight gain than quetiapine and olanzapine and less somnolence than quetiapine and ziprasidone. The findings suggest that MDD patients with mixed features can be reliably assessed, that paired site-based and site-independent assessments were generally concordant, and that ratings surveillance may reinforce ratings precision.
- |||||||||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck
Trial completion date, Trial primary completion date: Study of the Impact of Aripiprazole (Abilify (clinicaltrials.gov) - Apr 19, 2019 P4, N=47, Completed, The findings suggest that MDD patients with mixed features can be reliably assessed, that paired site-based and site-independent assessments were generally concordant, and that ratings surveillance may reinforce ratings precision. Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Nov 2018
- |||||||||| Latuda (lurasidone oral) / Sumitomo Dainippon
Effect of Chronic Lurasidone Treatment on Chronic Mild Stress-Induced Behavioral Deficits: The Potential Role for Glucocorticoid Receptor Signaling (Regency S-V) - Apr 3, 2019 - Abstract #SIRS2019SIRS_467; Discussion In summary, our results suggest that exposure to CMS produces complex changes in GR function and signaling, which may contribute to the behavioral abnormalities (anhedonia and cognitive impairment) found in stressed rats. The ability of chronic lurasidone to normalize such alterations provides further support on the potential of this novel antipsychotic to counteract molecular and functional changes that contribute to different domains of psychiatric disorders.
- |||||||||| Latuda (lurasidone oral) / Sumitomo Dainippon
Efficacy of Lurasidone in Antipsychotic-Nave Adolescents With Schizophrenia: Post-Hoc Analysis of a 6-Week, Randomized, Placebo-Controlled Study (Regency S-V) - Apr 3, 2019 - Abstract #SIRS2019SIRS_291; Discussion In this post-hoc analysis of a double-blind, 6-week study, adolescents experiencing an acute exacerbation of schizophrenia who had received no previous antipsychotic therapy were found to respond especially well to treatment with lurasidone at doses of 40 mg/d or 80 mg/d. Effect sizes at endpoint were notably larger for lurasidone vs. placebo (+60% for PANSS total and +255% for CGI-S endpoint scores) in the treatment-naïve group compared to patients with previous lifetime antipsychotic treatment.
- |||||||||| Latuda (lurasidone oral) / Sumitomo Dainippon
C-Reactive Protein and Response to Lurasidone Treatment in Adolescents With Schizophrenia (Regency S-V) - Apr 3, 2019 - Abstract #SIRS2019SIRS_211; Discussion In this post-hoc analysis utilizing data from a placebo-controlled study of adolescent patients with schizophrenia treated with lurasidone, our findings suggest improvement in cognitive performance can be associated with a combination of CRP and BMI at study baseline. Greater response to lurasidone treatment (vs. placebo) was observed in patients with lower systemic inflammation, and in overweight/obese patients with increased level of systemic inflammation at study baseline.
- |||||||||| lurasidone injection suspension (DSP-1349M) / Sumitomo Dainippon, Latuda (lurasidone oral) / Sumitomo Dainippon, Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
Preclinical, Journal: Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats. (Pubmed Central) - Mar 26, 2019 : These findings support our hypotheses in that lurasidone, in addition to a lack of effect on acute food intake and short term weight gain, can reduce olanzapine-induced food intake and weight gain in rats. This indicates the drug to have an active anti-hyperphagic mechanism, rather than solely the absence of a drug-induced weight gain that is such a severe limitation of drugs such as olanzapine.
- |||||||||| Moban (molindone) / Impax, Latuda (lurasidone oral) / Sumitomo Dainippon, Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
Retrospective data, Review, Journal: Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. (Pubmed Central) - Mar 25, 2019 The highest weight gain was found for clozapine, quetiapine and olanzapine...Risperidone, haloperidol, paliperidone and olanzapine were associated with prolactin increase...Most of the comparisons are based only on one study or just on indirect evidence. Nevertheless, the available direct and indirect evidence showed that the treatment effects were similar compared to findings in adult patients with schizophrenia.
- |||||||||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck
Trial completion, Enrollment change: Study of the Impact of Aripiprazole (Abilify (clinicaltrials.gov) - Feb 18, 2019 P4, N=47, Completed, Nevertheless, the available direct and indirect evidence showed that the treatment effects were similar compared to findings in adult patients with schizophrenia. Recruiting --> Completed | N=80 --> 47
- |||||||||| lurasidone / Generic mfg.
Trial completion: Pediatric Open-Label Extension Study (clinicaltrials.gov) - Dec 7, 2018 P3, N=702, Completed, Recruiting --> Completed | N=80 --> 47 Active, not recruiting --> Completed
- |||||||||| Cyclurad (cycloserine/lurasidone) / NeuroRx
Biomarker, Trial completion date, Trial initiation date, Trial primary completion date: NRX-GLX: NRX101 Glx Biomarker Validation Study (clinicaltrials.gov) - Nov 30, 2018 P2/3, N=24, Recruiting, Active, not recruiting --> Completed Trial completion date: Mar 2019 --> Feb 2020 | Initiation date: Mar 2018 --> Nov 2018 | Trial primary completion date: Mar 2019 --> Dec 2019
- |||||||||| Cyclurad (cycloserine/lurasidone) / NeuroRx
Trial completion date, Trial initiation date, Trial primary completion date: SBD-ASIB: NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation (clinicaltrials.gov) - Nov 30, 2018 P2/3, N=72, Not yet recruiting, Trial completion date: Mar 2019 --> Feb 2020 | Initiation date: Mar 2018 --> Nov 2018 | Trial primary completion date: Mar 2019 --> Dec 2019 Trial completion date: Mar 2019 --> Mar 2020 | Initiation date: May 2018 --> Jan 2019 | Trial primary completion date: Mar 2019 --> Dec 2019
- |||||||||| Cyclurad (cycloserine/lurasidone) / NeuroRx
Trial initiation date: MBD: NRX101 for Bipolar Depression and Sub-acute Suicidal Ideation and Behavior (clinicaltrials.gov) - Nov 30, 2018 P2/3, N=150, Not yet recruiting, Trial completion date: Mar 2019 --> Mar 2020 | Initiation date: May 2018 --> Jan 2019 | Trial primary completion date: Mar 2019 --> Dec 2019 Initiation date: Apr 2018 --> Jan 2019
- |||||||||| Cyclurad (cycloserine/lurasidone) / NeuroRx
Biomarker, Enrollment open: NRX-GLX: NRX101 Glx Biomarker Validation Study (clinicaltrials.gov) - Mar 19, 2018 P2/3, N=24, Recruiting, N=155 --> 72 Not yet recruiting --> Recruiting
- |||||||||| lurasidone / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: Pediatric Open-Label Extension Study (clinicaltrials.gov) - Mar 3, 2018 P3, N=702, Active, not recruiting, Not yet recruiting --> Recruiting Trial completion date: Oct 2018 --> Oct 2018 | Initiation date: Sep 2013 --> Sep 2013 | Trial primary completion date: Oct 2018 --> Oct 2018
- |||||||||| lurasidone / Generic mfg.
Enrollment change: Pediatric Open-Label Extension Study (clinicaltrials.gov) - Jul 6, 2017 P3, N=702, Active, not recruiting, Active, not recruiting --> Completed N=295 --> 702
- |||||||||| lurasidone / Generic mfg.
Enrollment closed, Trial primary completion date: Pediatric Open-Label Extension Study (clinicaltrials.gov) - Mar 6, 2017 P3, N=295, Active, not recruiting, N=3000 --> 10000 | Trial primary completion date: Feb 2017 --> Feb 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2018 --> Oct 2018
- |||||||||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck
Trial primary completion date: Study of the Impact of Aripiprazole (Abilify (clinicaltrials.gov) - Nov 10, 2016 P4, N=80, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Dec 2017
- |||||||||| lurasidone / Generic mfg.
Trial completion, Enrollment change: Illuminate: Lurasidone Pediatric Bipolar Study (clinicaltrials.gov) - Oct 11, 2016 P3, N=471, Completed, Initiation date: Jul 2016 --> Nov 2016 Recruiting --> Completed | N=340 --> 471
|